We are live on
!
Find out more
PR
PSP Research Portfolio holdings
AUM
$188M
This Fund
S&P 500
This Quarter
Est. Return
+18.09%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$114M
AUM Growth
–
Cap. Flow
+$110M
Cap. Flow
% of AUM
96.55%
Top 10 Holdings %
Top 10 Hldgs %
65.84%
Holding
85
New
85
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 0-3 Month Treasury Bond ETF
SGOV
|
+$70.3M |
| 2 |
Legend Biotech
LEGN
|
+$699K |
| 3 |
ACLX
Arcellx
ACLX
|
+$656K |
| 4 |
Amylyx Pharmaceuticals
AMLX
|
+$601K |
| 5 |
Mineralys Therapeutics
MLYS
|
+$594K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Stoke Therapeutics
STOK
$2.14B
| $528K | 0.46% |
+16,621
| New | +$500K |
|
52
Apogee Therapeutics
APGE
$10.2B
| $527K | 0.46% |
+6,984
| New | +$440K |
|
53
Crinetics Pharmaceuticals
CRNX
$9B
| $527K | 0.46% |
+11,316
| New | +$504K |
|
54
United Therapeutics
UTHR
$22.2B
| $526K | 0.46% |
+1,080
| New | +$503K |
|
|
MAZE
55
Maze Therapeutics
MAZE
$1.64B
| $525K | 0.46% |
+12,672
| New | +$436K |
|
56
Dianthus Therapeutics
DNTH
$6.2B
| $524K | 0.46% |
+12,725
| New | +$493K |
|
57
Denali Therapeutics
DNLI
$3.93B
| $524K | 0.46% |
+31,762
| New | +$536K |
|
58
Alnylam Pharmaceuticals
ALNY
$32B
| $524K | 0.46% |
+1,318
| New | +$583K |
|
59
Exelixis
EXEL
$13.9B
| $524K | 0.46% |
+11,948
| New | +$494K |
|
60
Xenon Pharmaceuticals
XENE
$6.18B
| $523K | 0.46% |
+11,678
| New | +$490K |
|
61
NewAmsterdam Pharma
NAMS
$3.28B
| $523K | 0.46% |
+14,920
| New | +$543K |
|
62
Celcuity
CELC
$4.65B
| $523K | 0.46% |
+5,244
| New | +$431K |
|
63
Kiniksa Pharmaceuticals
KNSA
$6.14B
| $522K | 0.46% |
+12,655
| New | +$508K |
|
64
BioMarin Pharmaceuticals
BMRN
$12.7B
| $521K | 0.46% |
+8,772
| New | +$478K |
|
65
Ocular Therapeutix
OCUL
$2.37B
| $520K | 0.45% |
+42,853
| New | +$521K |
|
66
Madrigal Pharmaceuticals
MDGL
$12.5B
| $519K | 0.45% |
+892
| New | +$456K |
|
67
Syndax Pharmaceuticals
SNDX
$1.79B
| $519K | 0.45% |
+24,716
| New | +$431K |
|
68
Spyre Therapeutics
SYRE
$8.25B
| $519K | 0.45% |
+15,840
| New | +$414K |
|
69
Viking Therapeutics
VKTX
$4.01B
| $518K | 0.45% |
+14,714
| New | +$521K |
|
70
Immunovant
IMVT
$9.07B
| $516K | 0.45% |
+20,305
| New | +$453K |
|
71
Beam Therapeutics
BEAM
$3.12B
| $508K | 0.44% |
+18,334
| New | +$468K |
|
72
Rhythm Pharmaceuticals
RYTM
$7.7B
| $507K | 0.44% |
+4,738
| New | +$503K |
|
73
Vera Therapeutics
VERA
$2.65B
| $506K | 0.44% |
+9,996
| New | +$355K |
|
74
Inhibrx
INBX
$1.84B
| $505K | 0.44% |
+6,389
| New | +$435K |
|
75
CRISPR Therapeutics
CRSP
$5.73B
| $502K | 0.44% |
+9,580
| New | +$574K |
|
Similar funds
IJWM
TCPG
KCPT
DWS
RMSCM
AWP
AIMA
CFP
PSP Research's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for PSP Research, which disclosed 85 positions worth $114M. Its ten largest holdings account for 66% of the portfolio.
Its largest position is iShares 0-3 Month Treasury Bond ETF: 700,000 shares worth $70.3M.
By sector, the portfolio is most concentrated in Healthcare at 39% of assets.
- PSP Research's largest Q4 2025 buy was iShares 0-3 Month Treasury Bond ETF: 700,000 shares worth $70.3M.
- PSP Research's ten largest holdings make up 66% of its $114M portfolio in Q4 2025.
- PSP Research disclosed 85 positions in Q4 2025, its first 13F filing on record.
Based on PSP Research's 13F filing for Q4 2025, filed 6 Feb 2026.